Infliximab: a review of its use in the treatment of Crohn's disease.
Infliximab is a chimeric monoclonal antibody to human tumor necrosis factor alpha. While its use was developed in the treatment of rheumatologic diseases its effects on Crohn's disease have revolutionized the management of this chronic illness. Infliximab has effects on both immune and epithelial ce...
| Published in: | Clinical Medicine: Therapeutics no. 1; pp. 1351 - 1366 |
|---|---|
| Main Authors: | , , |
| Format: | review Journal Article |
| Published: |
Sage Publications Inc.
2009
|
| Online Access: | View this record in EBSCOhost |